TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03909737
Drug: Azithromycin to pregnant women
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin to pregnant women at antenatal care visits and during delivery
Study: NCT03909737
Drug: Azithromycin to infants
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin to infants at 6 and 14 week EPI visits
Study: NCT03139136
Drug: MBS2320
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in the arm descriptions
Study: NCT03139136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in the arm descriptions
Study: NCT03079167
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00321906
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine 2mg/kg
Study: NCT02811991
Drug: Morhpine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
Study: NCT04642482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
Study: NCT01625442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets received daily for 45 days
Study: NCT03850834
Drug: placebo enteric-coated tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
Study: NCT02383901
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
Study: NCT02105285
Drug: OPC-1085EL ophthalmic solution
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00672607
Drug: extracts of Vitex agnus castus tablets
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
Study: NCT00672607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00004067
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV every 21 days for 4 cycles
Study: NCT01899820
Drug: Artemether lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether 20mg Lumefantrine 120mg
Study: NCT00640419
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
Study: NCT00640419
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
Study: NCT01643447
Drug: Diammonium glycyrrhizinate
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02472886
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01406314
Drug: GSK2315698
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion for approximately 48hours followed by subcutaneous injection
Study: NCT01051817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion
Study: NCT02077309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04808934
Drug: VKAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults receiving VKA
Study: NCT03155347
Drug: Placebo Matched to MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to MTX.
Study: NCT01821274
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Study: NCT01821274
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Study: NCT01800799
Drug: Baktar 800mg h.s.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agent (Baktar 800mg h.s.)
Study: NCT01800799
Drug: Celecoxib 200mg QD
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-inflammatory agent (Celecoxib 200mg QD)
Study: NCT01486823
Drug: MLDL1278A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
Study: NCT01486823
Drug: MLDL1278A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 360 mg MLDL1278A.
Study: NCT03635437
Drug: Gamma-Aminobutyric Acid (GABA)
Normalized name: GAMMA-AMINOBUTYRIC ACID (GABA) CAP/TAB
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
Study: NCT00355134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral administration.
Study: NCT01613183
Drug: Chinese herbal Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
Study: NCT03790865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injection
Study: NCT01634308
Drug: Bio-oss
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00990509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Study: NCT02581033
Drug: Nucleoside Analogue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
Study: NCT03698305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT02176512
Drug: BIBR 277 SE and HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A - fixed dose combination
Study: NCT02176512
Drug: BIBR 277 SE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B - Monocomponent
Study: NCT02532283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered placebo tablets orally twice daily for 7 days.
Study: NCT02853045
Drug: period with generic then period with drug (trade name)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The list of drugs is detailed in the study description
Study: NCT02194894
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen will be given for patient for both arms for 14 days
Study: NCT03518047
Drug: placebo for rizankizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for rizankizumab subcutaneous (SC) infusion
Study: NCT00255164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study: NCT01532102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel manufactured to appear identical to AP611074 5% gel
Study: NCT03770026
Drug: Saline cervical flushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
Study: NCT00002479
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00627523
Drug: Genotropin (PN-180,307) Somatropin
Normalized name: somatropin Cartridge [Genotropin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Genotropin
Study: NCT00627523
Drug: Control-no treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control-no treatment
Study: NCT02797795
Drug: NEV801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation
Study: NCT00208260
Drug: FOLFOX-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
Study: NCT00208260
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
Study: NCT03313531
Drug: Treatment with recombinant coagulation factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
Study: NCT02575378
Drug: Metronimic chemotherapy plus Chinese Traditional Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
Study: NCT01563731
Drug: all approved antihypertensive drugs; all approved statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
Study: NCT01533961
Drug: SCYX-7158
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01533961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00886366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single doses suspension
Study: NCT00886366
Drug: AZD6714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single doses a-d suspension
Study: NCT00886366
Drug: AZD6714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single doses d and g suspension
Study: NCT00279344
Drug: Fentanyl (Matrifen)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03619655
Drug: 18F-NaF PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
Study: NCT04508686
Drug: Capecitabine, camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single-arm study with all patients receiving these two drugs.
Study: NCT00707057
Drug: Ibuprofen 600 mg Extended-Release Tablets
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Study: NCT00707057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Study: NCT01003379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided with exactly the same shape, size and appearance.
Study: NCT00091468
Drug: Placebo transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
Study: NCT00780780
Drug: Triamcinolone + Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
Study: NCT00124891
Drug: GAP-486
Normalized name: GAP JUNCTION ALPHA-3 PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03200561
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 2mg/Kg/day for 5 days
Study: NCT02608996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For comparison to elucidate the true effect of nesiritide
Study: NCT00841945
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 50 mg / m² iv day 1 of each course
Study: NCT03924596
Drug: AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)
Normalized name: acetyl tetrapeptide-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
Study: NCT03654703
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophophamide
Study: NCT01401946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: flexible doses from 40 to 200 mg/d during 12 weeks
Study: NCT02609386
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Method of Administration: Cyclophosphamide is administered once by IV
Study: NCT02609386
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Method of Administration: Indomethacin is administered orally for 21 days.
Study: NCT04575090
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily.
Study: NCT04186624
Drug: Subacromial-subdeltoid bursa corticosteroid injection
Normalized name: Capsella bursa-pastoris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Study: NCT02858271
Drug: AKB-9778 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00148499
Drug: benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00459771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 32 mg, oral QD
Study: NCT00002692
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002692
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002692
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03464084
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing microcrystalline cellulose
Study: NCT04391179
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given for 14 days while in the hospital.
Study: NCT04553081
Drug: Dual versus triple therapy in treatment of HIV-1 infection.
Approvals — FDA: no, EMA: no, PMDA: no
Description: cfr arm description
Study: NCT04033406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% NaCl) given by intramuscular injection
Study: NCT00536510
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization.
Study: NCT01033630
Drug: D&G 2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
Study: NCT01033630
Drug: D&G 1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
Study: NCT01033630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Image-matched placebo, made with starch.
Study: NCT00699023
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02494856
Drug: Surgery with Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
Study: NCT02494856
Drug: Surgery with Naproxen and Esomeprazole
Normalized name: naproxen and esomeprazole
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
Study: NCT01673984
Drug: Decapeptyl® SR 22.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
Study: NCT01673984
Drug: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
Study: NCT00943397
Drug: Comparator: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
Study: NCT04335058
Drug: Lactoferrin + Iron Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin 100 mg twice daily +oral iron
Study: NCT04335058
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplement alone
Study: NCT04552600
Drug: Nuvastatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b Interventional, multi-centered, double-masked, randomized
Study: NCT01468454
Drug: 18 F-DOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
Study: NCT02750696
Drug: Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Study: NCT02750696
Drug: Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Study: NCT01384747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
Study: NCT01995344
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01720524
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
Study: NCT02183012
Drug: Ibuprofen extrudate
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01012999
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
Study: NCT02183012
Drug: Ibuprofen lysinate
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02183012
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01850394
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Study: NCT01488552
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study: NCT01488552
Drug: mFOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).